查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1944397

全球类肉瘤病药物市场：按作用机制、给药途径、药物类型、最终用途、年龄层、适应症、国家和地区划分－产业分析、市场规模、份额和预测（2025-2032）

Sarcoidosis Drug Market, By Mechanism of Action, By Route of Administration, By Drug, By Type, By End-Use, By Age Group, By Indication, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 329 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2024 年，类肉瘤病治疗市场价值将达到 72.011 亿美元，从 2025 年到 2032 年，复合年增长率将达到 6.12%。

类肉瘤病治疗市场涵盖用于治疗类肉瘤病的药物。结节性多发性硬化症是一种发炎性疾病，其特征是肺部、皮肤和淋巴结等器官中形成肉芽肿。自体免疫疾病和发炎性疾病盛行率的上升、诊断率的提高以及临床意识的增强是推动市场成长的关键因素。为了减轻副作用，市场正逐步从长期使用皮质类固醇转向免疫抑制剂和生物製药。然而，核准的疾病特异性药物寥寥无几，疾病的异质性仍是一个主要障碍。儘管如此，透过持续的临床研究、孤儿药的开发以及生物目标的研发，改善患者的长期预后和提高治疗的精准度仍蕴藏着新的机会。

结节性类肉瘤病硬化症药物的市场动态

更加重视研发

类肉瘤病治疗市场正日益受到研发工作的推动，这些研发工作旨在推动新型治疗方法的研发并改善病患的治疗效果。这种关注正促使标靶治疗和个人化医疗方法被广泛采用，以更好地应对疾病的临床复杂性。目前，结节性多发性硬化症的治疗主要依赖皮质类固醇和免疫抑制剂的仿单标示外用药，而这些药物往往有安全隐患且疗效不一。因此，开发替代治疗方案仍是当务之急。

例如，2025年2月，Roivant Sciences宣布计画启动一项针对成人皮肤类肉瘤病病患者的口服双重TYK2/JAK1抑制剂brepoxitinib的II期临床试验。该试验预计于2026年4月开始，结果预计于2026年下半年公布。

类肉瘤病治疗市场：細項分析

全球类肉瘤病药物市场按作用机制、给药途径、药物、类型、最终用途、年龄层、适应症和地区进行细分。

肺类肉瘤病以肺部肉芽肿为特征，是类肉瘤病治疗市场中最常见的类型（占所有类肉瘤病病患者的90%），因此占了相当大的份额。如此高的发生率凸显了针对肺部表现的标靶治疗和研究的必要性。其市场主导地位与高发病率、对创新治疗方法的持续探索以及医护人员和患者日益增强的认知密切相关。肺动脉高压和永久性肺纤维化等严重更凸显了标靶治疗的必要性。 2022年11月，Kinevant Sciences启动了RESOLVE-Lung试验，旨在评估靶向GM-CSF的单株抗体namilumab治疗肺类肉瘤病的疗效。该试验共有107名受试者，预计2024年底公布初步结果。

预计到2025年，泼尼松将在药物治疗市场占据主导地位，成为类肉瘤病治疗的主要药物。这主要归功于其作为类肉瘤病一线治疗药物的广泛认可。作为一种皮质类固醇，泼尼松能够降低免疫反应、发炎反应并缓解症状，尤其是在呼吸系统方面。临床指引始终推荐泼尼松作为标准治疗方案，凸显了其作为基础治疗的重要性。泼尼鬆的广泛接受度、价格适中以及在临床实践中的应用，使其成为医疗专业人员常用的长期治疗选择。泼尼鬆在控制发炎方面的有效性及其广泛的应用，巩固了其市场主导地位。根据2020年的一项研究，59.3%的类肉瘤病病患者接受了皮质类固醇治疗，其中24.7%的患者接受了长期治疗。长期使用以及显着的副作用，凸显了开发更安全、更有效治疗方法的必要性。

类肉瘤病药物市场－区域分析

北美地区在类肉瘤病治疗市场占据重要份额，这主要归功于该地区结节病病例高发，尤其是累及心臟的病例；此外，该地区拥有完善的医疗基础设施、活跃的研发项目，以及製药公司、学术机构、医学专家和患者权益组织之间的密切合作。北美地区成熟的医疗基础设施能够实现类肉瘤病的早期发现和强化治疗，为患者提供专业的治疗和最新的药物。随着领先的製药公司和研究机构携手合作，共用知识，加速疾病管理，类肉瘤病的治疗也不断取得进展。

2024 年 4 月，类肉瘤病研究基金会与沃尔格林合作，提高人们对类肉瘤病的认识，并在阿拉巴马州推广春季疫苗接种，强调结节病对社区的影响，并鼓励捐款以支持研究和患者支持倡议。

美国类肉瘤病药物市场—国家分析

2024年，美国类肉瘤病治疗市场在北美占据了显着的收入份额。这主要归功于该疾病在非裔美国人中的高发病率（非裔美国人尤其容易发展为重症），以及美国完善的医疗保健系统、广泛的研发活动和大型製药公司的强大影响力。美国患者能够获得先进的诊断技术和多种治疗方法，包括新型生物製药和孤儿药。对类肉瘤病研究的大力投入，以及学术机构与产业相关人员之间的战略合作，正在推动市场成长，并使美国成为类肉瘤病治疗药物研发和推广领域的领导者。

目录

第一章类肉瘤病药物市场概览

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章 结节性类肉瘤病药物的主要市场趋势

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 未来市场趋势

第四章类肉瘤病治疗市场：产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长展望：概览
  • 管理体制分析

第五章类肉瘤病药物市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章 结节性类肉瘤病药物市场状况

  • 类肉瘤病治疗市占率分析（2024 年）
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

第七章 依作用机转分類的类肉瘤病治疗市场

  • 概述
    • 细分市场占有率分析：依作用机制划分
    • 抗疟疾药
    • 免疫抑制剂
    • 肿瘤坏死因子-α (TNF-α) 抑制剂
    • 皮质类固醇

第八章类肉瘤病药物市场依给药途径划分

  • 概述
    • 细分市场占有率分析：依管理途径
    • 注射
    • 口服
    • 局部的

第九章类肉瘤病药物市场（依药物分类）

  • 概述
    • 细分市场占有率分析：依药物划分
    • 羟氯喹
    • Azathioprine
    • 促肾上腺皮质激素
    • 地塞米松
    • 秋水仙碱
    • Chloroquine
    • 强的松
    • 胺基甲基叶酸
    • 德尔塔区

第十章 按类型分類的类肉瘤病药物市场

  • 概述
    • 细分市场占有率分析：按类型
    • 肝类肉瘤病
    • 肾类肉瘤病
    • 脾臟和骨髓类肉瘤病
    • 肺结节类肉瘤病
    • 肌肉骨骼类肉瘤病
    • 皮肤类肉瘤病
    • 眼部类肉瘤病
    • 心臟类肉瘤病
    • 类肉瘤病

第十一章 依最终用途分類的类肉瘤病治疗市场

  • 概述
    • 细分市场占有率分析：依最终用途划分
    • 手术中心
    • 医院和诊所
    • 诊断中心
    • 其他的

第十二章 按年龄组别分類的类肉瘤病药物市场

  • 概述
    • 细分市场占有率分析：依年龄组别划分
    • 儿童
    • 成人
    • 老年人

第十三章类肉瘤病药物市场（依适应症划分）

  • 概述
    • 细分市场占有率分析：依指标
    • 肺外结节类肉瘤病
    • 肺结节类肉瘤病

第十四章 各地区类肉瘤病治疗市场

  • 介绍
  • 北美洲
    • 概述
    • 北美主要製造商
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲主要製造商
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他的
  • 亚太地区
    • 概述
    • 亚太地区主要製造商
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他的
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他的
  • 中东和非洲
    • 概述
    • 中东和非洲的主要製造商
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他的

第十五章 主要供应商分析—类肉瘤病治疗产业

  • 竞争对手仪錶板
    • 竞争基准
    • 竞争定位
  • 公司简介
    • Janssen Pharmaceutical Companies of Johnson &Johnson
    • Pfizer Inc
    • Amgen Inc.
    • Bristol Myers Squibb
    • Novartis AG
    • Kinevant Sciences GmbH
    • Molecure SA
    • aTyr Pharma
    • Merck &Co., Inc
    • Xentria
    • United Therapeutics Corporation
    • Relief Therapeutics
    • Mallinckrodt
    • AbbVie Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • GSK plc.
    • Theravance Biopharma
    • Others

第十六章：分析师视角

简介目录
Product Code: ANV6020

Sarcoidosis Drug Market size was valued at US$ 7,201.10 Million in 2024, expanding at a CAGR of 6.12% from 2025 to 2032.

The Sarcoidosis Drug Market includes pharmaceutical therapies used to treat sarcoidosis, an inflammatory disease characterized by granuloma formation in organs such as the lungs, skin, and lymph nodes. The rising prevalence of autoimmune and inflammatory disorders, increased diagnosis rates, and improved clinical awareness are the primary drivers of market growth. To reduce side effects, the market is gradually shifting away from long-term corticosteroid use and toward immunosuppressants and biologic therapies. However, there are few disease-specific drugs that have been approved, and disease heterogeneity is still a major barrier. Despite this, opportunities are emerging through ongoing clinical research, orphan drug development, and targeted biologics to improve long-term patient outcomes and treatment precision.

Sarcoidosis Drug Market- Market Dynamics

Increased emphasis on research and development

The sarcoidosis drug market is increasingly shaped by intensive research and development efforts aimed at advancing novel therapies and enhancing patient outcomes. This focus has encouraged the adoption of targeted treatments and personalized medicine approaches to better manage the disease's clinical complexity. At present, treatment largely depends on the off-label use of corticosteroids and immunosuppressants, which are often associated with safety concerns and variable therapeutic effectiveness. Consequently, the development of alternative treatment options remains a critical priority.

For instance, in February 2025, Roivant Sciences announced plans to initiate a Phase II clinical trial of brepocitinib, an oral dual TYK2 and JAK1 inhibitor, for the treatment of adults with cutaneous sarcoidosis. The study is scheduled to commence in April 2026, with results anticipated in the latter half of 2026.

Sarcoidosis Drug Market- Segmentation Analysis:

The Global Sarcoidosis Drug Market is segmented on the basis of Mechanism of Action, Route of Administration, Drug, Type, End-Use, Age Group, Indication, and Region.

The pulmonary sarcoidosis segment accounts for a significant share of the sarcoidosis drug market because it is distinguished by the presence of granulomas in the lungs and is the most common type of sarcoidosis, affecting 90% of people. The high prevalence highlights the need for targeted treatments and investigations into pulmonary symptoms. Market dominance is associated with higher prevalence rates, ongoing research into innovative therapies, and increased awareness among healthcare providers and patients. Serious conditions like pulmonary hypertension and permanent lung fibrosis highlight the need for targeted treatments. In November 2022, Kinevant Sciences initiated the RESOLVE-Lung study to evaluate namilumab, a monoclonal antibody that targets GM-CSF, for the treatment of pulmonary sarcoidosis. The study, which included 107 participants, is expected to produce preliminary findings by the end of 2024.

Based on the Drug: Prednisone dominate the sarcoidosis drug market in 2025 because it is widely recognized as the primary treatment for sarcoidosis. As a corticosteroid, it reduces immune response, inflammation, and symptoms, particularly in respiratory cases. Clinical guidelines consistently recommend prednisone as the standard therapy, emphasizing its importance as a foundational treatment. Its widespread acceptance, affordability, and clinical familiarity make it a popular choice among healthcare professionals for prolonged treatment. Prednisone's effectiveness in inflammation management, combined with its widespread use, contributed to its market prevalence. According to the 2020 study, 59.3% of sarcoidosis patients are treated with corticosteroids, while 24.7% receive long-term treatment. The prolonged use, combined with significant side effects, emphasizes the need for safer and more effective treatment options.

Sarcoidosis Drug Market- Geographical Insights

North America holds significant share in the sarcoidosis drug market due to its high prevalence, especially with cardiac involvement, robust healthcare infrastructure, active research and development programs, and partnerships between pharmaceutical companies, academic entities, healthcare professionals, and patient advocacy organizations. The region's well-established healthcare infrastructure allows early detection and thorough management of sarcoidosis, providing patients with specialized treatment and the latest medicines. Sarcoidosis therapy advances with major pharmaceutical companies and research organizations, which collaborate to share knowledge and accelerate disease management.

In April 2024, the Foundation for Sarcoidosis Research partnered with Walgreens to raise sarcoidosis awareness and promote spring vaccinations in Alabama, emphasizing community impact and encouraging donations to research and patient assistance initiatives.

United States Sarcoidosis Drug Market- Country Insights

The U.S. sarcoidosis drug market accounted for a sizable revenue share in North America in 2024, owing to the disease's high prevalence, particularly among African Americans, who frequently suffer from more severe forms of the disease. This is complemented by a well-developed healthcare system, extensive research and development activities, and a strong presence of major pharmaceutical corporations. Patients in the United States have access to advanced diagnostics and a wide range of therapies, including novel biologics and orphan drugs. Strong funding for sarcoidosis research, as well as strategic collaborations between academic institutions and industry players, are driving market growth and establishing the United States as a leader in sarcoidosis drug development and adoption.

Sarcoidosis Drug Market- Competitive Landscape:

The sarcoidosis drug market is moderately competitive, with established pharmaceutical companies and emerging players offering anti-inflammatory, immunosuppressive, and biologic therapies. Market participants compete primarily based on product efficacy, safety profiles, and expanded indications. Corticosteroids remain the primary first-line treatment, but immunosuppressants and biologics are gaining popularity for chronic and refractory cases. Companies are also investing in clinical trials and pipeline expansion to meet unmet medical needs, particularly for steroid-free treatments. Strategic collaborations, research partnerships, and regulatory approvals all play an important role in maintaining market positions. Key players in the sarcoidosis drug market include Novartis AG, Kinevant Sciences GmbH, Molecure S.A, aTyr Pharma, all of which rely on strong R&D capabilities and global distribution networks to stay competitive.

In November 2024, The Foundation for Sarcoidosis Research awarded Dr. Eliot Peyster and Dr. Ravi Karra USD 100,000 to advance the diagnosis and treatment of cardiac sarcoidosis, with a focus on establishing new diagnostic benchmarks and reusing imaging agents.

Recent Developments:

In April 2024, aTyr Pharma has launched a global Phase III EFZO-FIT(TM) trial to assess efzofitimod, an innovative treatment aimed at neuropilin-2 for pulmonary sarcoidosis that has been granted orphan drug designations in the U.S., EU, and Japan.

In March 2025, Xentria, Inc. reported significant progress in its XTMAB-16 study for pulmonary sarcoidosis, including the successful enrollment of patients in the dose-ranging study. XTMAB-16 is a new anti-TNF-a monoclonal antibody being developed as a potential treatment for pulmonary sarcoidosis. This advancement demonstrates Xentria's commitment to addressing the unmet need for targeted therapies in sarcoidosis, with the next phase of research, which will include additional patient screening, set to begin in Fall 2025.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SARCOIDOSIS DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Pfizer Inc
  • Amgen Inc.
  • Bristol Myers Squibb
  • Novartis AG
  • Kinevant Sciences GmbH
  • Molecure S.A
  • aTyr Pharma
  • Merck & Co., Inc
  • Xentria
  • United Therapeutics Corporation
  • Relief Therapeutics
  • Mallinckrodt
  • AbbVie Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • GSK plc.
  • Theravance Biopharma
  • Others

GLOBAL SARCOIDOSIS DRUG MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

  • Antimalarial
  • Immunosuppressants
  • Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
  • Corticosteroid

GLOBAL SARCOIDOSIS DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Injectable
  • Oral
  • Topical

GLOBAL SARCOIDOSIS DRUG MARKET, BY DRUG- MARKET ANALYSIS, 2019 - 2032

  • Hydroxychloroquine
  • Azathioprine
  • Corticotropin
  • Dexamethasone
  • Colchicine
  • Chloroquine
  • Prednisone
  • Methotrexate
  • Deltasone

GLOBAL SARCOIDOSIS DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hepatic Sarcoidosis
  • Renal Sarcoidosis
  • Sarcoidosis of the Spleen and Bone Marrow
  • Pulmonary Sarcoidosis
  • Musculoskeletal Sarcoidosis
  • Cutaneous Sarcoidosis
  • Ocular Sarcoidosis
  • Cardiac Sarcoidosis
  • Neurosarcoidosis

GLOBAL SARCOIDOSIS DRUG MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Surgical Centers
  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

GLOBAL SARCOIDOSIS DRUG MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Pediatric
  • Adult
  • Geriatric

GLOBAL SARCOIDOSIS DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Extrapulmonary Sarcoidosis
  • Pulmonary Sarcoidosis

GLOBAL SARCOIDOSIS DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Sarcoidosis Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Sarcoidosis Drug Market Snippet by Mechanism of Action
    • 2.1.2. Sarcoidosis Drug Market Snippet by Route of Administration
    • 2.1.3. Sarcoidosis Drug Market Snippet by Drug
    • 2.1.4. Sarcoidosis Drug Market Snippet by Type
    • 2.1.5. Sarcoidosis Drug Market Snippet by End-Use
    • 2.1.6. Sarcoidosis Drug Market Snippet by Age Group
    • 2.1.7. Sarcoidosis Drug Market Snippet by Indication
    • 2.1.8. Sarcoidosis Drug Market Snippet by Country
    • 2.1.9. Sarcoidosis Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Sarcoidosis Drug Key Market Trends

  • 3.1. Sarcoidosis Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Sarcoidosis Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Sarcoidosis Drug Market Opportunities
  • 3.4. Sarcoidosis Drug Market Future Trends

4. Sarcoidosis Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Sarcoidosis Drug Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Sarcoidosis Drug Market Landscape

  • 6.1. Sarcoidosis Drug Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Sarcoidosis Drug Market - By Mechanism of Action

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
    • 7.1.2. Antimalarial
    • 7.1.3. Immunosuppressants
    • 7.1.4. Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
    • 7.1.5. Corticosteroid

8. Sarcoidosis Drug Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Injectable
    • 8.1.3. Oral
    • 8.1.4. Topical

9. Sarcoidosis Drug Market - By Drug

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug, 2024 & 2032 (%)
    • 9.1.2. Hydroxychloroquine
    • 9.1.3. Azathioprine
    • 9.1.4. Corticotropin
    • 9.1.5. Dexamethasone
    • 9.1.6. Colchicine
    • 9.1.7. Chloroquine
    • 9.1.8. Prednisone
    • 9.1.9. Methotrexate
    • 9.1.10. Deltasone

10. Sarcoidosis Drug Market - By Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 10.1.2. Hepatic Sarcoidosis
    • 10.1.3. Renal Sarcoidosis
    • 10.1.4. Sarcoidosis of the Spleen and Bone Marrow
    • 10.1.5. Pulmonary Sarcoidosis
    • 10.1.6. Musculoskeletal Sarcoidosis
    • 10.1.7. Cutaneous Sarcoidosis
    • 10.1.8. Ocular Sarcoidosis
    • 10.1.9. Cardiac Sarcoidosis
    • 10.1.10. Neurosarcoidosis

11. Sarcoidosis Drug Market - By End-Use

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End-Use, 2024 & 2032 (%)
    • 11.1.2. Surgical Centers
    • 11.1.3. Hospitals & Clinics
    • 11.1.4. Diagnostic Centers
    • 11.1.5. Others

12. Sarcoidosis Drug Market - By Age Group

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
    • 12.1.2. Pediatric
    • 12.1.3. Adult
    • 12.1.4. Geriatric

13. Sarcoidosis Drug Market - By Indication

  • 13.1. Overview
    • 13.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 13.1.2. Extrapulmonary Sarcoidosis
    • 13.1.3. Pulmonary Sarcoidosis

14. Sarcoidosis Drug Market- By Geography

  • 14.1. Introduction
    • 14.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 14.2. North America
    • 14.2.1. Overview
    • 14.2.2. Sarcoidosis Drug Key Manufacturers in North America
    • 14.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.2.4. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.2.6. North America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.2.7. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.2.8. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.2.9. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.2.10. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.2.11. U.S.
      • 14.2.11.1. Overview
      • 14.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.11.3. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.2.11.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.2.11.5. U.S. Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.11.6. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.11.7. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.11.8. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.2.11.9. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.2.12. Canada
      • 14.2.12.1. Overview
      • 14.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.12.3. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.2.12.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.2.12.5. Canada Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.12.6. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.12.7. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.12.8. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.2.12.9. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.3. Europe
    • 14.3.1. Overview
    • 14.3.2. Sarcoidosis Drug Key Manufacturers in Europe
    • 14.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.3.4. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.3.6. Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.3.7. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.3.8. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.3.9. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.3.10. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.11. Germany
      • 14.3.11.1. Overview
      • 14.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.11.3. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.11.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.11.5. Germany Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.11.6. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.11.7. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.11.8. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.11.9. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.12. UK
      • 14.3.12.1. Overview
      • 14.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.12.3. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.12.4. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.12.5. UK Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.12.6. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.12.7. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.12.8. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.12.9. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.13. France
      • 14.3.13.1. Overview
      • 14.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.13.3. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.13.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.13.5. France Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.13.6. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.13.7. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.13.8. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.13.9. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.14. Italy
      • 14.3.14.1. Overview
      • 14.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.14.3. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.14.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.14.5. Italy Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.14.6. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.14.7. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.14.8. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.14.9. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.15. Spain
      • 14.3.15.1. Overview
      • 14.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.15.3. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.15.4. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.15.5. Spain Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.15.6. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.15.7. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.15.8. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.15.9. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.16. The Netherlands
      • 14.3.16.1. Overview
      • 14.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.16.3. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.16.4. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.16.5. The Netherlands Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.16.6. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.16.7. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.16.8. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.16.9. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.17. Sweden
      • 14.3.17.1. Overview
      • 14.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.17.3. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.17.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.17.5. Sweden Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.17.6. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.17.7. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.17.8. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.17.9. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.18. Russia
      • 14.3.18.1. Overview
      • 14.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.18.3. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.18.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.18.5. Russia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.18.6. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.18.7. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.18.8. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.18.9. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.19. Poland
      • 14.3.19.1. Overview
      • 14.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.19.3. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.19.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.19.5. Poland Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.19.6. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.19.7. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.19.8. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.19.9. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.20. Rest of Europe
      • 14.3.20.1. Overview
      • 14.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.20.3. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.20.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.20.5. Rest of the Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.20.6. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.20.7. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.20.8. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.20.9. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.4. Asia Pacific (APAC)
    • 14.4.1. Overview
    • 14.4.2. Sarcoidosis Drug Key Manufacturers in Asia Pacific
    • 14.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.4.4. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.4.5. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.4.6. APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.4.7. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.4.8. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.4.9. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.4.10. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.11. China
      • 14.4.11.1. Overview
      • 14.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.11.3. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.11.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.11.5. China Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.11.6. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.11.7. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.11.8. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.11.9. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.12. India
      • 14.4.12.1. Overview
      • 14.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.12.3. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.12.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.12.5. India Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.12.6. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.12.7. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.12.8. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.12.9. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.13. Japan
      • 14.4.13.1. Overview
      • 14.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.13.3. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.13.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.13.5. Japan Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.13.6. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.13.7. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.13.8. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.13.9. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.14. South Korea
      • 14.4.14.1. Overview
      • 14.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.14.3. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.14.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.14.5. South Korea Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.14.6. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.14.7. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.14.8. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.14.9. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.15. Australia
      • 14.4.15.1. Overview
      • 14.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.15.3. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.15.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.15.5. Australia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.15.6. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.15.7. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.15.8. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.15.9. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.16. Indonesia
      • 14.4.16.1. Overview
      • 14.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.16.3. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.16.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.16.5. Indonesia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.16.6. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.16.7. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.16.8. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.16.9. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.17. Thailand
      • 14.4.17.1. Overview
      • 14.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.17.3. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.17.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.17.5. Thailand Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.17.6. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.17.7. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.17.8. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.17.9. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.18. Philippines
      • 14.4.18.1. Overview
      • 14.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.18.3. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.18.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.18.5. Philippines Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.18.6. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.18.7. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.18.8. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.18.9. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.19. Rest of APAC
      • 14.4.19.1. Overview
      • 14.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.19.3. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.19.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.19.5. Rest of APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.19.6. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.19.7. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.19.8. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.19.9. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.5. Latin America (LATAM)
    • 14.5.1. Overview
    • 14.5.2. Sarcoidosis Drug Key Manufacturers in Latin America
    • 14.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.5.4. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.5.5. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.5.6. LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.5.7. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.5.8. LATAM Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.5.9. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.5.10. LATAM Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.11. Brazil
      • 14.5.11.1. Overview
      • 14.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.11.3. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.11.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.11.5. Brazil Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.11.6. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.11.7. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.11.8. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.11.9. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.12. Mexico
      • 14.5.12.1. Overview
      • 14.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.12.3. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.12.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.12.5. Mexico Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.12.6. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.12.7. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.12.8. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.12.9. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.13. Argentina
      • 14.5.13.1. Overview
      • 14.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.13.3. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.13.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.13.5. Argentina Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.13.6. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.13.7. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.13.8. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.13.9. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.14. Colombia
      • 14.5.14.1. Overview
      • 14.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.14.3. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.14.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.14.5. Colombia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.14.6. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.14.7. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.14.8. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.14.9. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.15. Rest of LATAM
      • 14.5.15.1. Overview
      • 14.5.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.15.3. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.15.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.15.5. Rest of LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.15.6. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.15.7. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.15.8. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.15.9. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.6. Middle East and Africa
    • 14.6.1. Overview
    • 14.6.2. Sarcoidosis Drug Key Manufacturers in Middle East and Africa
    • 14.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.6.4. Middle East and Africa Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.6.6. Middle East and Africa Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.6.7. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.6.8. Middle East and Africa Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.6.9. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.6.10. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.11. Saudi Arabia
      • 14.6.11.1. Overview
      • 14.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.11.3. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.11.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.11.5. Saudi Arabia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.11.6. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.11.7. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.11.8. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.11.9. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.12. United Arab Emirates
      • 14.6.12.1. Overview
      • 14.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.12.3. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.12.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.12.5. United Arab Emirates Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.12.6. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.12.7. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.12.8. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.12.9. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.13. Israel
      • 14.6.13.1. Overview
      • 14.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.13.3. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.13.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.13.5. Israel Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.13.6. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.13.7. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.13.8. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.13.9. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.14. Turkey
      • 14.6.14.1. Overview
      • 14.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.14.3. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.14.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.14.5. Turkey Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.14.6. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.14.7. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.14.8. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.14.9. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.15. Algeria
      • 14.6.15.1. Overview
      • 14.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.15.3. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.15.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.15.5. Algeria Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.15.6. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.15.7. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.15.8. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.15.9. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.16. Egypt
      • 14.6.16.1. Overview
      • 14.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.16.3. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.16.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.16.5. Egypt Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.16.6. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.16.7. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.16.8. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.16.9. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.17. Rest of MEA
      • 14.6.17.1. Overview
      • 14.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.17.3. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.17.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.17.5. Rest of MEA Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.17.6. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.17.7. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.17.8. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.17.9. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

15. Key Vendor Analysis- Sarcoidosis Drug Industry

  • 15.1. Competitive Benchmarking
    • 15.1.1. Competitive Dashboard
    • 15.1.2. Competitive Positioning
  • 15.2. Company Profiles
    • 15.2.1. Janssen Pharmaceutical Companies of Johnson & Johnson
    • 15.2.2. Pfizer Inc
    • 15.2.3. Amgen Inc.
    • 15.2.4. Bristol Myers Squibb
    • 15.2.5. Novartis AG
    • 15.2.6. Kinevant Sciences GmbH
    • 15.2.7. Molecure S.A
    • 15.2.8. aTyr Pharma
    • 15.2.9. Merck & Co., Inc
    • 15.2.10. Xentria
    • 15.2.11. United Therapeutics Corporation
    • 15.2.12. Relief Therapeutics
    • 15.2.13. Mallinckrodt
    • 15.2.14. AbbVie Inc.
    • 15.2.15. Kyorin Pharmaceutical Co., Ltd.
    • 15.2.16. Boehringer Ingelheim International GmbH
    • 15.2.17. Sanofi
    • 15.2.18. GSK plc.
    • 15.2.19. Theravance Biopharma
    • 15.2.20. Others

16. 360 Degree Analyst View

17. Appendix

  • 17.1. Research Methodology
  • 17.2. References
  • 17.3. Abbreviations
  • 17.4. Disclaimer
  • 17.5. Contact Us